Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Incidence of VES in NZW and Watanabe hearts when serial perfusion (40 min) was conducted in the presence of PD-145065 (nonselective ET antagonist, 10 µmol/liter), A-127722 (ETA antagonist, 20 µmol/liter), BQ-123 (ETA antagonist, 2 µmol/liter) and phosphoramidon (Phrd, ECE inhibitor, 50 µmol/liter) (n = 6 per group). #, p < 0.05; ##, p < 0.01 vs. separate perfusion; *, p < 0.05; **, p < 0.01 vs. serial perfusion without intervention.
|
